Novo Nordisk A/S (NVO)
NYSE: NVO · Real-Time Price · USD
58.08
-4.80 (-7.63%)
At close: Apr 17, 2025, 4:00 PM
58.80
+0.72 (1.24%)
After-hours: Apr 17, 2025, 7:59 PM EDT
Novo Nordisk Revenue
In the year 2024, Novo Nordisk had annual revenue of 290.40B DKK with 25.03% growth. Novo Nordisk had revenue of 85.68B in the quarter ending December 31, 2024, with 30.09% growth.
Revenue (ttm)
290.40B DKK
Revenue Growth
+25.03%
P/S Ratio
7.06
Revenue / Employee
n/a
Employees
n/a
Market Cap
284.50B USD
Revenue Chart
* This company reports financials in DKK.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 290.40B | 58.14B | 25.03% |
Dec 31, 2023 | 232.26B | 55.31B | 31.26% |
Dec 31, 2022 | 176.95B | 36.15B | 25.68% |
Dec 31, 2021 | 140.80B | 13.85B | 10.91% |
Dec 31, 2020 | 126.95B | 4.93B | 4.04% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
NVO News
- 23 hours ago - Novo Nordisk: A Price Too Low To Ignore - Seeking Alpha
- 1 day ago - Novo Nordisk May Lag Behind Eli Lilly In Cardiometabolic Race, Analyst Downgrades Stock - Benzinga
- 3 days ago - Trump signs healthcare executive order that includes a win for pharma companies - Reuters
- 4 days ago - The Tariff Game Just Changed: 7 Blue-Chip Bargains To Buy Now - Seeking Alpha
- 4 days ago - Trump says US pharma tariffs coming in not-too-distant future - Reuters
- 4 days ago - Novo Nordisk warns consumers about counterfeit versions of Ozempic in US - Reuters
- 5 days ago - Wegovy, Zepbound makers' stocks rally as a weight-loss-drug competitor drops out - Market Watch
- 7 days ago - Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages - CNBC